Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation

Drug Discovery Today

Volumn 22, Issue 2, 2017, Pages 299-313

  Gentile, Eugenia ^a   Liuzzi, Grazia M ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; BIOLOGICAL PRODUCT; MATRIX METALLOPROTEINASE INHIBITOR;

CENTRAL NERVOUS SYSTEM; CNIDARIA; CRUSTACEA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; MOLLUSC; NERVOUS SYSTEM INFLAMMATION; NEUROPHARMACOLOGY; NONHUMAN; PROTEIN TARGETING; REVIEW; SPONGE (PORIFERA); UROCHORDATA; ANIMAL; INFLAMMATION; METABOLISM; NEUROLOGIC DISEASE;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NERVOUS SYSTEM DISEASES;

EID: 84992322924     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.09.023     Document Type: Review

References (115)

1. 1 Nagase, H., Woessner, J.F., Matrix metalloproteinases. J. Biol. Chem. 274 (1999), 2149–21494.
2. 2 Kim, Y.S., Joh, T.H., Matrix metalloproteinases, new insights into the understanding of neurodegenerative disorders. Biomol. Ther. 20 (2012), 133–143.
3. 3 Amar, S., Fields, G.B., Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Exp. Rev. Prot. 12 (2015), 445–447.
4. 4 Dufour, A., Overall, C.M., Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34 (2013), 233–242.
5. 5 Manello, F., Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?. Recent Pat. Anti-Cancer Drug Deliv. 1 (2006), 91–103.
6. 6 Zhang, C., Kim, S.K., Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Mar. Drugs 7 (2009), 71–84.
7. 7 Jackson, B.C., et al. Update of human and mouse matrix metalloproteinase families. Hum. Genomics 4 (2010), 194–201.
8. 8 Cauwe, B., et al. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42 (2007), 113–185.
9. 9 Page-McCaw, A., et al. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8 (2007), 221–233.
10. 10 Murphy, G., Nagase, H., Progress in matrix metalloproteinase research. Mol. Aspects Med. 29 (2008), 290–308.
11. 11 Ra, H.J., Parks, W.C., Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26 (2007), 587–596.
12. 12 Van den Steen, P.E., et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37 (2002), 375–536.
13. 13 Baker, A.H., et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115 (2002), 3719–3727.
14. 14 Agrawal, S.M., et al. MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19 (2008), 42–51.
15. 15 Larsen, P.H., et al. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci. 26 (2006), 2207–2214.
16. 16 Barros, C.S., Extracellular matrix: functions in the nervous system. Cold Spring Harb. Perspect. Biol., 3, 2011, a005108.
17. 17 Fujioka, H., et al. Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem. Res. Int., 2012, 10.1155/2012/789083789083.
18. 18 Soleman, S., et al. Targeting the neuronal extracellular matrix in neurological disorders. Neuroscience 253 (2013), 194–213.
19. 19 Bingol, B., Sheng, M., Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 69 (2011), 22–32.
20. 20 Meighan, S.E., et al. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J. Neurochem. 96 (2006), 1227–1241.
21. 21 Ethell, I.M., Ethell, D.W., Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J. Neurosci. Res. 85 (2007), 2813–2823.
22. 22 Singh, D., et al. Multifaceted role of matrix metalloproteinases (MMPs). Front. Mol. Biosci., 2015, 10.3389/fmolb.2015.00019.
23. 23 Vandooren, J., et al. On the structure and functions of gelatinase B/matrix metalloproteinase-9 in neuroinflammation. Prog. Brain Res. 214 (2014), 193–206.
24. 24 Yong, V.W., Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6 (2005), 931–944.
25. 25 Rosenberg, G.A., Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 8 (2009), 205–216.
26. 26 Rosenberg, G.A., Metalloproteinases and neurodegenerative diseases: pathophysiological and therapeutic perspectives. Metalloproteinases Med. 2 (2015), 39–50.
27. 27 Jian, L.K., Rosenberg, G.A., Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic. Biol. Med. 39 (2005), 71–80.
28. 28 Gasche, Y., et al. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood–brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21 (2001), 1393–1400.
29. 29 Yang, Y., et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27 (2007), 697–709.
30. 30 Chelluboina, B., et al. Matrix metalloproteinase-12 induces blood–brain barrier damage after focal cerebral ischemia. Stroke 46 (2015), 3523–3531.
31. 31 Gu, Y., et al. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood–brain barrier permeability in focal cerebral ischemia and reperfusion injury. J. Neurochem. 120 (2012), 147–156.
32. 32 Asahi, M., et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20 (2000), 1681–1689.
33. 33 Lee, S.R., et al. Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci. 26 (2006), 3491–3495.
34. 34 Gijbels, K., et al. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41 (1992), 29–34.
35. 35 Waubant, E., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53 (1999), 1397–1401.
36. 36 Liuzzi, G.M., et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult. Scler. 8 (2002), 222–228.
37. 37 Rosenberg, G.A., et al. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood–brain barrier injury. Neurology 46 (1996), 1626–1632.
38. 38 Trojano, M., et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing–remitting MS. Neurology 53 (1999), 1402–1408.
39. 39 Avolio, C., et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 136 (2003), 46–53.
40. 40 Cuzner, M.L., et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55 (1996), 1194–1204.
41. 41 Maeda, A., Sobel, R.A., Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55 (1996), 300–309.
42. 42 Liuzzi, G.M., et al. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult. Scler. 10 (2004), 290–297.
43. 43 Proost, P., et al. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192 (1993), 1175–1181.
44. 44 Opdenakker, G., et al. Remnant epitopes, autoimmunity and glycosylation. Biochim. Biophys. Acta 1760 (2006), 610–615.
45. 45 Gearing, A.J., et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370 (1994), 555–557.
46. 46 Rosenberg, G.A., Matrix metalloproteinase-mediated neuroinflammation in vascular cognitive impairment of the Binswanger type. Cell. Mol. Neurobiol. 36 (2016), 195–202.
47. 47 Ihara, M., et al. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J. Cereb. Blood Flow Metab. 21 (2001), 828–834.
48. 48 Nakaji, K., et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke 37 (2006), 2816–2823.
49. 49 Rosenberg, G.A., et al. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 32 (2001), 1162–1168.
50. 50 Deb, S., Gottschall, P.E., Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J. Neurochem. 66 (1996), 1641–1647.
51. 51 Backstrom, J.R., et al. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1–40). J. Neurosci. 16 (2003), 7910–7919.
52. 52 Lorenzl, S., et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem. Int. 43 (2003), 191–196.
53. 53 Yoshiyama, Y., et al. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer's disease brain. Acta Neuropathol. 99 (2000), 91–95.
54. 54 Selkoe, D.J., Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb. Clin. Neurol. 89 (2008), 245–260.
55. 55 Lorenzl, S., et al. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp. Neurol. 178 (2002), 13–20.
56. 56 Kim, Y.S., et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 21 (2007), 179–187.
57. 57 Choi, D.H., et al. Role of matrix metalloproteinase 3-mediated alpha synuclein cleavage in dopaminergic cell death. J. Biol. Chem. 286 (2011), 14168–14177.
58. 58 Kim, Y.S., et al. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25 (2005), 3701–3711.
59. 59 Choi, D.H., et al. A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J. Neurochem. 106 (2008), 405–415.
60. 60 Choi, D.H., et al. DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death. Antioxid. Redox. Signal. 14 (2011), 2137–2150.
61. 61 He, X., et al. Association studies of MMP-9 in Parkinson's disease and amyotrophic lateral sclerosis. PLOS ONE, 8, 2013, e73777.
62. 62 Zhao, B.Q., et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12 (2006), 441–445.
63. 63 Hsu, J.-Y.C., et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J. Neurosci. 26 (2006), 9841–9850.
64. 64 Yin, K.J., et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 26 (2006), 10939–10948.
65. 65 Yan, P., et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281 (2006), 24566–24574.
66. 66 Uhm, J.H., et al. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 22 (1998), 53–63.
67. 67 Larsen, P.H., et al. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 23 (2003), 11127–11135.
68. 68 Hu, J., et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. 6 (2007), 480–498.
69. 69 Yiotakis, A., Dive, V., Third-generation MMP inhibitors: recent advances in the development of highly selective inhibitors. Edwards, D., et al. (eds.) The Cancer Degradome, 2008, Springer, 811–825.
70. 70 Seo, U.K., et al. Large-scale and effective screening of Korean medicinal plants for inhibitory activity on matrix metalloproteinase-9. J. Ethnopharmacol. 97 (2005), 101–106.
71. 71 Thomas, N.V., Kim, S., Metalloproteinase inhibitors: status and scope from marine organisms. Biochem. Res. Int., 2010, 10.1155/2010/845975.
72. 72 Thomas, N.V., et al. Potential matrix metalloproteinase inhibitors from edible marine algae: a review. Environ. Toxicol. Pharmacol. 37 (2014), 1090–1100.
73. 73 Fujita, M., et al. Ageladine A: an antiangiogenic matrix metalloproteinase inhibitor from the marine sponge Agelas nakamurai. J. Am. Chem. Soc. 125 (2003), 15700–15701.
74. 74 Fujita, M., et al. Ancorinosides B–D, inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP), from the marine sponge Penares sollasi Thiele. Tetrahedron 57 (2001), 1229–1234.
75. 75 Rodríguez-Nieto, S., et al. Anti-angiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J. 16 (2002), 261–263.
76. 76 Fujita, M., et al. Callysponginol sulfate A, an MT1-MMP inhibitor isolated from the marine sponge Callyspongia truncata. J. Nat. Prod. 66 (2003), 569–571.
77. 77 Shin, J., et al. New macrolides from the sponge Chondrosia corticata. J. Nat. Prod. 67 (2004), 1889–1892.
78. 78 Bae, S.Y., et al. Anti-proliferative effect of (19Z)-halichondramide, a novel marine macrolide isolated from the sponge Chondrosia corticata, is associated with G2/M cell cycle arrest and suppression of mTOR signaling in human lung cancer cells. In Vitro Toxicol. 27 (2012), 694–699.
79. 79 Shin, Y., et al. Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge Chondrosia corticata, on human prostate cancer cells via modulation of epithelial-to-mesenchymal transition. Mar. Drugs 11 (2013), 2472–2485.
80. 80 Di Bari, G., et al. Inhibitory effect of aqueous extracts from marine sponges on the activity and expression of gelatinases A (MMP-2) and B (MMP-9) in rat astrocyte cultures. PLOS ONE, 10, 2015, e0129322.
81. 81 Lin, Y.Y., et al. A soft coral-derived compound, 11-epi-sinulariolide acetate suppresses inflammatory response and bone destruction in adjuvant-induced arthritis. PLOS ONE, 8, 2013, e6292.
82. 82 Lin, J.J., et al. 11-Epi-sinulariolide acetate reduces cell migration and invasion of human hepatocellular carcinoma by reducing the activation of ERK1/2, p38MAPK and FAK/PI3K/AKT/mTOR signaling pathways. Mar. Drugs 12 (2014), 4783–4798.
83. 83 Lee, H.P., et al. Lemnalol attenuates mast cell activation and osteoclast activity in a gouty arthritis model. J. Pharm. Pharmacol. 67 (2015), 274–285.
84. 84 Hong, S.H., et al. Ascidian tunicate extracts attenuate rheumatoid arthritis in a collagen-induced murine model. Nat. Prod. Commun. 9 (2014), 847–851.
85. 85 Piperigkou, Z., et al. Biochemical and toxicological evaluation of nano-heparins in cell functional properties, proteasome activation and expression of key matrix molecules. Toxicol. Lett. 240 (2016), 32–42.
86. 86 Wang, H., et al. Mere15, a novel polypeptide from Meretrix meretrix, inhibits adhesion, migration and invasion of human lung cancer A549 cells via down-regulating MMPs. Pharm. Biol. 51 (2013), 145–151.
87. 87 Nguyen, V.T., et al. Matrix metalloproteinases (MMPs) inhibitory effects of an octameric oligopeptide isolated from abalone Haliotis discus hannai. Food Chem. 141 (2013), 503–509.
88. 88 Brito, A.S., et al. Anti-inflammatory properties of a heparin-like glycosaminoglycan with reduced anti-coagulant activity isolated from a marine shrimp. Bioorg. Med. Chem. 16 (2008), 9588–9595.
89. 89 Senthilkumar, K., Kim, S.K., Marine invertebrate natural products for anti-inflammatory and chronic diseases. Evid. Based Complement. Alternat. Med., 2013, 2013, 572859.
90. 90 Russo, P., et al. New drugs from marine organisms in Alzheimer's disease. Mar. Drugs, 14, 2015, 5.
91. 91 Mayer, A.M.S., et al. Marine pharmacology in 2005–6: marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. Acta 1790 (2009), 283–308.
92. 92 Mayer, A.M.S., et al. Marine pharmacology in 2009–2011: marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar. Drugs 11 (2013), 2510–2573.
93. 93 Tsang, C.K., et al. Sargachromenol, a novel nerve growth factor-potentiating substance isolated from Sargassum macrocarpum, promotes neurite outgrowth and survival via distinct signaling pathways in PC12D cells. Neuroscience 132 (2005), 633–643.
94. 94 Kisa, F., et al. Constituents of Holothuroidea. 17. Isolation and structure of biologically active monosialo-gangliosides from the sea cucumber Cucumaria echinata. Chem. Pharm. Bull. 54 (2006), 982–987.
95. 95 Kisa, F., et al. Constituents of Holothuroidea. 18. Isolation and structure of biologically active disialo- and trisialo-gangliosides from the sea cucumber Cucumaria echinata. Chem. Pharm. Bull. 54 (2006), 1293–1298.
96. 96 Inagaki, M., et al. Biologically active glycosides from asteroidea. 43. Isolation and structure of a new neuritogenic-active ganglioside molecular species from the starfish Linckia laevigata. Chem. Pharm. Bull. 53 (2005), 1551–1554.
97. 97 Higuchi, R., et al. Biologically active glycosides from asteroidea. 42. Isolation and structure of a new biologically active ganglioside molecular species from the starfish Asterina pectinifera. Chem. Pharm. Bull. 54 (2006), 287–291.
98. 98 Loughnan, M., et al. Identification of a novel class of nicotinic receptor antagonists: dimeric conotoxins VxXIIA. Biochim. Biophys. Acta 281 (2006), 24745–24755.
99. 99 Muttenthaler, M., et al. Structure–activity studies on alpha-conotoxins. Curr. Pharm. Des. 17 (2011), 4226–4241.
100. 100 Tsuneki, H., et al. Marine alkaloids (−)-pictamine and (−)-lepadin B block neuronal nicotinic acetylcholine receptors. Biol. Pharm. Bull. 28 (2005), 611–614.
101. 101 Langjae, R., et al. Acetylcholinesterase-inhibiting steroidal alkaloid from the sponge Corticium sp. Steroids 72 (2007), 682–685.
102. 102 Teichert, R.W., Olivera, B.M., Neuroprotective effects of marine algae. Future Med. Chem. 2 (2010), 731–774.
103. 103 Wen, L., et al. SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons. Br. J. Pharmacol. 145 (2005), 728–739.
104. 104 Olivera, B.M., w-Conotoxin MVIIA: from marine snail venom to analgesic drug. Fusetani, N., (eds.) Drugs from the Sea, 2000, Karger, 75–85.
105. 105 Aiello, A., et al. Novel bioactive bromopyrrole alkaloids from the Mediterranean sponge Axinella verrucosa. Bioorg. Med. Chem. 14 (2006), 17–24.
106. 106 Tasdemir, R., et al. Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J. Med. Chem. 45 (2002), 529–532.
107. 107 To, K.C., The anti-invasive compound motuporamine C is a robust stimulator of neuronal growth cone collapse. Neuroscience 139 (2006), 1263–1274.
108. 108 Chen, W.F., et al. Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson's model: a promising candidate for the treatment of Parkinson's disease. Naunyn. Schmiedebergs Arch. Pharmacol. 385 (2012), 265–275.
109. 109 Temraz, T.A., et al. A pyridinium derivative from Red Sea soft corals inhibited voltage-activated potassium conductances and increased excitability of rat cultured sensory neurones. BMC Pharmacol., 6, 2006, 10.
110. 110 Jean, Y.H., et al. Capnellene, a natural marine compound derived from soft coral, attenuates chronic constriction injury-induced neuropathic pain in rats. Br. J. Pharm. 158 (2009), 713–725.
111. 111 Devy, L., Dransfield, D.T., New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting of membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int., 11, 2011, 191670.
112. 112 Nagase, H.G.M., Tailoring TIMPs for selective metalloproteinase inhibition. Edwards, D., et al. (eds.) The Cancer Degradome: Proteases and Cancer Biology, 2008, Springer, 787–810.
113. 113 Proksch, P., et al. Drugs from the sea – current status and microbiological implications. Appl. Microbiol. Biotechnol. 59 (2002), 125–134.
114. 114 Haefner, B., Drugs from the deep: marine natural products as drug candidates. Drug Discov. Today 8 (2003), 536–544.
115. 115 Mayer, A.M.S., Lehmann, V.K.B., Marine pharmacology. Pharmacologist 42 (2000), 62–69.